Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Recurrence 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Ovarian Diseases 1Neoplasms, Glandular and Epithelial 1Genital Neoplasms, Female 1Fallopian Tube Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Abdominal Neoplasms 1

Interventions

pembrolizumab 6Paclitaxel 5Carboplatin 4Bevacizumab 3oregovomab 2Nivolumab 2Hyperthermic Intraperitoneal Chemotherapy 2Cisplatin 2tislelizumab 1spartalizumab 1rucaparib 1olaparib 1niraparib 1lenvatinib 1fludarabine phosphate 1fludarabine 1denileukin diftitox 1anlotinib 1Surveys and Questionnaires 1Saline Solution 1Ramucirumab 1Platinum 1Nutrition Assessment 1Neoadjuvant Therapy 1Leucovorin 1Irinotecan 1Immunotherapy, Adoptive 1Glucose 1Gemcitabine 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Ovarian Epithelial × Cell Count × Clear all
NCT05617755 2025-07-30

AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

Arsenal Biosciences, Inc.

Phase 1 Active not recruiting
19 enrolled
Gynecologic

Abdominal Neoplasms, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡